QuantaLife, a life science tool company developing PCR systems, has received an National Institutes of Health (NIH) grant of $6m over 5 years for the development of technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections.

QuantaLife said that the project will be funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the NIH.

QuantaLife is currently building a new instrument system for droplet digitalPCR, that will detect and quantify DNA/RNA targets.

The NIH grant will allow QuantaLife to broaden its product pipeline and build a platform test for detecting the antibiotic resistant bacteria that cause MRSA infections in collaboration with the University of Mississippi Medical Center.

QuantaLife chief science officer Ben Hindson said that the award provides independent validation of QuantaLife’s ddPCR platform and will accelerate the development of their next-generation diagnostic platform.